Phase II Trial of Aminopterin in Patients With Persistent or Recurrent Endometrial Carcinoma

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically confirmed persistent, recurrent, or refractory
endometrial carcinoma who have failed prior first line chemotherapy Bidimensionally
measurable disease by physical exam or medical imaging techniques (sonography acceptable
if lesion(s) are clearly defined and measurable in two dimensions) Ascites and pleural
effusions are not measurable

PATIENT CHARACTERISTICS: Age: Not specified Performance status: GOG 0-2 Life expectancy:
At least 2 months Hematopoietic: WBC at least 3,000/mm3 Platelet count at least
100,000/mm3 Granulocyte count at least 1,500/mm3 Hemoglobin at least 8 g/dL Hepatic:
Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT no greater than 3
times ULN Alkaline phosphatase no greater than 3 times ULN Renal: Creatinine no greater
than 2.0 mg/dL Other: Not pregnant or nursing Negative pregnancy test Fertile patients
must use effective contraception No significant infection

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
Characteristics At least 4 weeks since prior chemotherapy and recovered Endocrine therapy:
Not specified Radiotherapy: At least 4 weeks since prior radiotherapy and recovered
Surgery: At least 4 weeks since prior surgery and recovered Other: At least 4 weeks since
any prior therapy directed at malignant endometrial tumor(s) At least 4 weeks since prior
folate-containing vitamins No concurrent folate-containing vitamins No other concurrent
anticancer therapy